'Acute coronary syndromes' diaporamas de présentation

NCLEX RN Preparation Program

NCLEX RN Preparation Program. Cardiovascular Disorders Module 5, Part 2 of 3. Introduction The heart and the circulatory system comprise one of the most essential parts of the body. Failure to function results in death of the organism. Cardiovascular System.

1.6k views • 94 slides

Acute Coronary Syndromes

Acute Coronary Syndromes. Henry Z. Pitzele, MD, FACEP Deputy Chief, Section of Emergency Medicine Jesse Brown VA Medical Center, Chicago, IL. Overview. Why? Pathophysiology Treatment. Definition. Acute Myocardial Infarction Troponin Symptoms Q or STD PCI Unstable Angina

811 views • 62 slides

Intense Insulin Therapy in Diabetics after Myocardial Infarction : An underutilized therapy ?

Intense Insulin Therapy in Diabetics after Myocardial Infarction : An underutilized therapy ?. Jeffrey Hyde M.D. December 7, 1999 Resident Grand Rounds. CASE PRESENTATION.

952 views • 60 slides

Chest Pain

Chest Pain. LSU Medical Student Clerkship, New Orleans, LA. Goals Review the pathophysiology, diagnosis and treatment of life threatening causes of chest pain. Epidemiology 5% of all ED visits Approximately 5 million visits per year. Visceral Pain

864 views • 56 slides

Statin in Acute Coronary Syndrome

Statin in Acute Coronary Syndrome. By C. Wongvipaporn Division Cardiology, Medicine Department Faculty of Medicine, Khon Kaen University. Acute Myocardial Infarction. AMI is fatal in about 30-50% of cases Approximately 50% of AMI deaths occur within 1 hour of symptom onset.

2.66k views • 43 slides

CARDIAC INSUFFICIENCY

CARDIAC INSUFFICIENCY. FROM THE ED TO THE ICU: OLD THERAPIES AND NEW DRUGS. WILLIAM MALLON MD FACEP LAC + USC MEDICAL CENTER. CARDIAC DISEASE. Hypertensive cardiomyopathy Ischemic cardiomyopathy Cor pulmonale Alcoholic cardiomyopathy Infectious cardiomyopathy

668 views • 43 slides

DUAL ANTIPLATELET THERAPY (DAPT)

DUAL ANTIPLATELET THERAPY (DAPT) . BHAVI SHAH, DNP, APRN, ANP-C UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER DEPARTMENT OF MEDICINE CARDIOLOGY SECTION. WHAT REALLY HAPPENS. Normal endothelium regulates blood flow Tissue Injury Vasoconstriction Release of von Willebrand Factor ( vWF )

1.1k views • 36 slides

Acute Hypertension

Acute Hypertension. Jay Patel, MD CR FIRM C. Initial Evaluation. What are the vitals? EKG Is this new or old? What has the rate of increase been? Is the patient mentating well? Are there signs of acute end-organ damage?. Acute Hypertension. Is it urgent or emergent?

614 views • 36 slides

Local improvement following national clinical audit workshops Auditing heart attacks Saving lives

Local improvement following national clinical audit workshops Auditing heart attacks Saving lives. Dr Andrew Wragg Barts Health. Overview. National Audits related to Acute Coronary syndromes What do they involve What are our challenges How do we use data: how does it change practice

408 views • 31 slides

ANTIANGINAL DRUGS

ANTIANGINAL DRUGS. ANTIANGINAL DRUGS. ILOs. By the end of those 2 lectures [24 slides for studing ] you will be able to: Recognize variables contributing to a balanced myocardial supply vs demand Identify etiopathogenic cascades contributing to ischemic heart disease

555 views • 26 slides

ANTIANGINAL DRUGS

ANTIANGINAL DRUGS. ANTIANGINAL DRUGS. ILOs. By the end of those 2 lectures [24 slides for studing ] you will be able to: Recognize variables contributing to a balanced myocardial supply vs demand Identify etiopathogenic cascades contributing to ischemic heart disease

656 views • 24 slides

Upalni biljezi u akutnom koronarnom sindromu

439 views • 23 slides

The Safety and Tolerability of Atopaxar (E5555) in the Treatment of Patients with Acute Coronary Syndromes: The LANCE

The Safety and Tolerability of Atopaxar (E5555) in the Treatment of Patients with Acute Coronary Syndromes: The LANCELOT-ACS Trial.

585 views • 22 slides

The Safety and Tolerability of Atopaxar (E5555) in the Treatment of Patients with Acute Coronary Syndromes: The LANCE

The Safety and Tolerability of Atopaxar (E5555) in the Treatment of Patients with Acute Coronary Syndromes: The LANCELOT-ACS Trial.

362 views • 22 slides

Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents

Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents. Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust. NO CONFLICT OF INTEREST TO DECLARE. Intra-Coronary Thrombus. What are the Characteristics of an Ideal Anti-Platelet Agent?. Effective. Rapid Onset.

434 views • 21 slides

Cardiology Jeopardy

902 views • 21 slides

AMERICAN HEART ASSOCIATION

646 views • 16 slides

Case Study Analysis

Case Study Analysis. Chris Kwan PBL 28. Investigation - ECG. Investigation - Echo. Presentation. Mr Fafnir Dryke , aged 49, presents into your clinic His presenting complaints include: Dyspnoea Chest pain Faintness Bruises on his arm and face Swollen R. knee, walks in with a limp.

215 views • 9 slides

Insights from clinical trials : The unassailable case for LDL-c lowering

Master class: Exploring the clinical innovations in lipid management? June 4-5, 2010, Barcelona. Insights from clinical trials : The unassailable case for LDL-c lowering. Kausik Ray, MD St Georges University London, United Kingdom. Prof. Kausik Ray: Biography.

171 views • 6 slides

FACULTY:

116 views • 2 slides